Patton Albertson Miller Group LLC Purchases 567 Shares of Stryker Corporation $SYK

Patton Albertson Miller Group LLC raised its position in shares of Stryker Corporation (NYSE:SYK) by 3.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,902 shares of the medical technology company’s stock after acquiring an additional 567 shares during the quarter. Patton Albertson Miller Group LLC’s holdings in Stryker were worth $6,291,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Mogy Joel R Investment Counsel Inc. boosted its position in Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company’s stock valued at $36,561,000 after acquiring an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. boosted its position in shares of Stryker by 1.9% during the 1st quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company’s stock worth $65,096,000 after purchasing an additional 3,341 shares in the last quarter. Harbor Capital Advisors Inc. bought a new position in shares of Stryker during the 1st quarter worth about $1,840,000. Mar Vista Investment Partners LLC boosted its position in shares of Stryker by 10.2% during the 1st quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock worth $33,572,000 after purchasing an additional 8,353 shares in the last quarter. Finally, United Services Automobile Association bought a new position in shares of Stryker during the 1st quarter worth about $2,857,000. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.1%

NYSE:SYK opened at $368.83 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The firm has a market cap of $141.01 billion, a price-to-earnings ratio of 48.85, a price-to-earnings-growth ratio of 2.66 and a beta of 0.93. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The firm has a 50-day moving average price of $385.71 and a two-hundred day moving average price of $379.08.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter last year, the business posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Insider Activity at Stryker

In other news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Wells Fargo & Company raised their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research report on Friday, August 1st. Rothschild & Co Redburn initiated coverage on shares of Stryker in a research report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target on the stock. Redburn Partners set a $420.00 price target on shares of Stryker in a research report on Thursday, September 18th. Finally, Evercore ISI raised their price target on shares of Stryker from $390.00 to $415.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Fourteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $430.33.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.